The purpose of this study is to learn the dose of the investigational drug 153Sm-EDTMP that can be given to patients with cancer or those whom have not responded to therapy with surgery and chemotherapy. The study will also evaluate the side effects of this drug. 153Sm-EDTMP was eliminated relatively quickly after each infusion with uptake remaining in metastases or skeleton only by 24 hr. Bladder toxicity has not occurred. We are currently using IV hydration as the only means of cystitis prevention. Total body radiation levels on day 13 have been consistently very low, well below 1 mRem/hr at 1 meter safety limit. All patients have had stem cells infused 14 days after high dose 153Sm-EDTMP. Stem cell infusions have been given as outpatient observation with side effects limited to those usually associated with DMSO cryopreservative (temporary nausea, anorexia for 4-6 hrs). All patients have become temporarily pancytopenic after 153Sm-EDTMP. Once ANC is less than 500, patients have been provided with G-CSF to speed neutrophil recovery. Platelet transfusion requirements have been variable. Most patients have required only 1-3 platelet transfusions for platelet counts <20,000. Some but not all patients have also been transfused with packet red blood cells. Recovery of neutrophil count has generally occurred before day 14. No serious infections have been documented. Only 1 patient out of 8 has had a hospital admission associated with fever and antibiotic administration during neutropenia. The fever was probably catheter related and resolved with catheter removal. Since all patients have recovered from hematopoietic toxicity within 30 days, stem cell support successfully ameliorated hematopoietic toxicity in all patients treated with high dose 153Sm-EDTMP. Furthermore, since no serious non-hematologic toxicities have been seen, stem cell infusion offers promise of a means to escalate doses of 153Sm-EDTMP to even higher levels.

Project Start
1999-12-01
Project End
2000-11-30
Budget Start
Budget End
Support Year
29
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Yu, Alan S L; Shen, Chengli; Landsittel, Douglas P et al. (2018) Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 93:691-699
Kamimura, Daisuke; Suzuki, Takeki; Wang, Wanmei et al. (2018) Higher plasma leptin levels are associated with reduced left ventricular mass and left ventricular diastolic stiffness in black women: insights from the Genetic Epidemiology Network of Arteriopathy (GENOA) study. Hypertens Res 41:629-638
Nowak, Kristen L; You, Zhiying; Gitomer, Berenice et al. (2018) Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease. J Am Soc Nephrol 29:571-578
Tirumanisetty, P; Prichard, D; Fletcher, J G et al. (2018) Normal values for assessment of anal sphincter morphology, anorectal motion, and pelvic organ prolapse with MRI in healthy women. Neurogastroenterol Motil 30:e13314
McKenzie, Katelyn A; El Ters, Mirelle; Torres, Vicente E et al. (2018) Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort. BMC Nephrol 19:378
Dad, Taimur; Abebe, Kaleab Z; Bae, K Ty et al. (2018) Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep 3:619-624
Brosnahan, Godela M; Abebe, Kaleab Z; Rahbari-Oskoui, Frederic F et al. (2017) Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials. Curr Hypertens Rev 13:109-120
Kamimura, Daisuke; Suzuki, Takeki; Furniss, Anna L et al. (2017) Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness. J Cardiovasc Med (Hagerstown) 18:954-961
Chung, Jin Ook; Koutsari, Christina; Blachnio-Zabielska, Agnieszka U et al. (2017) Intramyocellular Ceramides: Subcellular Concentrations and Fractional De Novo Synthesis in Postabsorptive Humans. Diabetes 66:2082-2091
West, Nancy A; Lirette, Seth T; Cannon, Victoria A et al. (2017) Adiposity, Change in Adiposity, and Cognitive Decline in Mid- and Late Life. J Am Geriatr Soc 65:1282-1288

Showing the most recent 10 out of 1267 publications